Lv3
370 积分 2022-12-11 加入
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
10天前
已完结
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
11天前
已完结
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial
17天前
已完结
Recurrence and Circulating Tumor DNA in Human Papillomavirus-Positive Oropharyngeal Cancer: A Meta-Analysis
1个月前
已完结
Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689
1个月前
已关闭
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial
1个月前
已完结
[Radiation or Surgery for HPV-positive oropharyngeal cancer? The ORATOR2 Trial - Comparing apples and oranges]
1个月前
已完结
Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline
1个月前
已完结
Leveraging the Potential of Induction Therapy in Human Papillomavirus–Mediated Oropharyngeal Carcinoma
1个月前
已完结
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
